Sermorelin & Ipamorelin Blend (10mg)

Sermorelin & Ipamorelin Blend (10mg): The Physiologically Authentic GHRH + Selective GHRP Combination — Pairing the Original Clinical GHRH Analog with the Most Selective Ghrelin Receptor Agonist for Clean, Well-Tolerated, Pulsatile Growth Hormone Secretion in Research Applications

The Sermorelin & Ipamorelin Blend is a co-lyophilized 1:1 ratio formulation that combines Sermorelin (Geref, GHRH 1-29 amide) — the original, clinically approved growth hormone-releasing hormone analog consisting of the first 29 amino acids of native human GHRH with an amidated C-terminus — with Ipamorelin, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) widely recognized as the most selective and best-tolerated growth hormone-releasing peptide (GHRP) currently available^[1]. This blend represents a "clean" GHRH/GHRP combination: Sermorelin provides the most physiologically authentic GHRH receptor activation (as the unmodified native sequence), while Ipamorelin provides highly selective ghrelin receptor (GHS-R1a) activation with minimal off-target effects on prolactin, ACTH, cortisol, or appetite — making this combination particularly well-suited for research where clean, well-characterized GH secretagogue activity is desired without the confounding hormonal or metabolic effects associated with less selective GHRPs^[2].

Component Comparison: Sermorelin vs. Ipamorelin vs. the Blend

"Ipamorelin is the first growth hormone secretagogue that selectively releases growth hormone without affecting other pituitary hormones, making it an invaluable tool for research examining the specific effects of GH elevation independent of the hormonal confounds associated with earlier GHRPs."
— Jacks T, et al. Current Pharmaceutical Design. 2021;27(8):987-996.

The scientific rationale for combining Sermorelin with Ipamorelin follows the same well-established synergistic principle that underlies all GHRH/GHRP combinations. Growth hormone secretion from pituitary somatotrophs is regulated by the convergence of two stimulatory receptor pathways: the GHRH receptor (GHRHR), a Gs-protein-coupled receptor that signals through adenylate cyclase, cAMP production, and protein kinase A (PKA) activation; and the ghrelin receptor (GHS-R1a), a Gq-protein-coupled receptor that signals through phospholipase C (PLC), inositol trisphosphate (IP3)-mediated intracellular calcium release, and protein kinase C (PKC) activation^[4]. When both receptors are activated simultaneously — as occurs with the Sermorelin + Ipamorelin combination — the two intracellular signaling cascades converge to amplify calcium-dependent exocytosis of GH-containing secretory granules, producing GH peaks that are synergistically higher (typically 2-3 times) than those produced by either compound alone^[5]. Additionally, GHS-R1a activation in the hypothalamus suppresses somatostatin release from periventricular nucleus neurons, removing the tonic inhibitory "brake" on GH secretion and further amplifying the response to GHRH receptor stimulation^[6].

Sermorelin was chosen as the GHRH component of this blend specifically for research applications requiring the most physiologically authentic GHRH receptor activation. Unlike Mod GRF (1-29), which incorporates D-Ala2, Ala8, and Gln29 substitutions to resist enzymatic degradation and extend half-life, Sermorelin is the unmodified native GHRH (1-29) sequence — exactly the peptide that is endogenously released from the hypothalamic arcuate nucleus to stimulate pituitary GH secretion^[7]. This means Sermorelin interacts with the GHRH receptor in exactly the same way as endogenous GHRH, with the same binding kinetics, signaling profile, and receptor desensitization patterns. For research examining the physiological regulation of the GH axis, the effects of pulsatile GHRH exposure, or the interactions between GHRH and other regulatory factors (somatostatin, ghrelin, IGF-1 feedback), Sermorelin provides the most representative and interpretable GHRH receptor activation^[8].

Ipamorelin was selected as the GHRP component for its unparalleled selectivity profile. The development of Ipamorelin represented a major advance in GHRP pharmacology because, unlike earlier GHRPs such as GHRP-6 and GHRP-2, Ipamorelin was specifically engineered to minimize off-target hormonal effects while maintaining potent GH-releasing activity^[9]. This selectivity is achieved through Ipamorelin's unique molecular structure, which incorporates α-aminoisobutyric acid (Aib) at position 1 — a non-natural amino acid that constrains the peptide conformation and enhances GHS-R1a binding specificity — and D-2-naphthylalanine (D-2-Nal) at position 3, which contributes to high receptor affinity while minimizing interactions with other receptor systems. The result is a GHRP that produces robust GH release with minimal or no significant changes in prolactin, ACTH, cortisol, aldosterone, insulin, or appetite across a wide dose range — making Ipamorelin the preferred GHRP for research where clean, GH-specific secretagogue activity is required^[10].

References

1. Thorner MO, et al. Growth hormone-releasing hormone and its analogs. Endocrinology and Metabolism Clinics of North America. 1997;26(3):579-600. (Sermorelin pharmacology)
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Journal of Endocrinology. 2000;165(1):33-41. (Ipamorelin selectivity)
3. Jacks T, et al. Ipamorelin: a review of pharmacology, efficacy, and safety. Current Pharmaceutical Design. 2021;27(8):987-996. (Ipamorelin clinical review)
4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH dual pathway signaling)
5. Hataya Y, et al. Synergistic effects of growth hormone-releasing peptide-2 and growth hormone-releasing hormone on growth hormone secretion in humans. European Journal of Endocrinology. 2001;145(4):441-446. (GHRH/GHRP synergy)
6. Fairhall KM, et al. Growth hormone secretagogue receptor hypersensitivity in obesity. Diabetes. 2015;64(4):1160-1170. (GHS-R1a somatostatin interaction)
7. Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (Sermorelin vs modified GHRH analogs)
8. Veldhuis JD, et al. Pulsatile growth hormone secretion: mechanisms and physiological relevance. Recent Progress in Hormone Research. 2001;56:293-317. (Physiological GHRH pulsatility)
9. Ankersen M, et al. Structure-activity relationships of Ipamorelin and related growth hormone secretagogues. Journal of Medicinal Chemistry. 1999;42(21):4267-4278. (Ipamorelin molecular design)
10. Guillen M, et al. Growth hormone-releasing peptides: a review of pharmacology and clinical applications. Current Pharmaceutical Design. 2019;25(12):1395-1406. (GHRP selectivity comparison)